AUSTIN, Texas, Oct. 27, 2015 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. today announced it conducted a new audio interview with PositiveID Corporation (“PositiveID” or the “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions. In the interview, which can be heard at http://smallcapvoice.com/blog/10-26-15-smallcapvoice-interview-with-positiveid-corporation-psid, William J. Caragol, Chairman and CEO of PositiveID, discusses the Company’s recent acquisition news and overall acquisition strategy.
Last week PositiveID announced it entered into an agreement to acquire Thermomedics Inc. and the FDA-cleared Caregiver® non-contact thermometer. The acquisition is a part of the Company’s overall growth strategy to add revenue-generating, complementary products with significant market penetration potential to its portfolio. PositiveID expects to close the acquisition during the fourth quarter of 2015.
Caregiver®, the world’s first non-contact device with TouchFree™ technology, is a clinical-grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants. Since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination and decreases costs for healthcare facilities.
PositiveID remains focused on its Firefly Dx polymerase chain reaction (“PCR”) breadboard prototype pathogen detection system, designed to provide real-time, accurate diagnostic results in less than 20 minutes from a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment, highly trained personnel, and can take hours or even days to provide results. Firefly's applications include point-of-need, lab-quality, detection of pathogenic organisms; agricultural and food screening in both domestic sectors and developing countries; and detection of biological agents associated with weapons of mass destruction.
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company that develops biological detection systems for point-of-need testing and America’s homeland defense industry. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID's future expectations in this press release and those made in its interview with SmallCapVoice.com, including the likelihood that PositiveID expects to close the acquisition during the fourth quarter of 2015; the likelihood that Firefly can lead to treatment scenarios at the point of need that are not possible with existing systems; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include, without limitation, PositiveID’s ability to target the bio-threat detection and rapid medical testing sectors; PositiveID’s ability to complete the development and commercialization of its Firefly Dx system; as well as other risks. Additional information about these and other factors that could affect PositiveID’s business is set forth in its various filings with the Securities and Exchange Commission, including those set forth in PositiveID’s 10-K filed on March 30, 2015, and 10-Qs filed on August 13, 2015, May 15, 2015, and November 17, 2014, under the caption “Risk Factors.” PositiveID undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.